Long-term Survival after Hematopoietic Cell Transplant for Sickle Cell Disease Compared to the United States Population
Andrew St. Martin(Johns Hopkins Hospital), Mary Eapen(Medical College of Wisconsin), Thomas DeSain(Harvard University), Paul Avillach(Harvard University), Vianney Jouhet(Harvard University), Patricia Steinert(Medical College of Wisconsin), Arnaud Serret-Larmande(Harvard University), Jessica C. Lyons(University of North Carolina at Chapel Hill), Kyle Hebert(Harvard University), Emily Hughes(Harvard University), Danielle Pillion(Harvard University), Jason Stedman(Harvard University)
Cited by 17
Related Papers
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research
|Quality of Life Research|2013|855
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
|New England Journal of Medicine|2022|457
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide
|Journal of Clinical Oncology|2017|325
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
|Journal of Clinical Oncology|2021|247